David Liu
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 54
- Cancer Immunotherapy and Biomarkers 24
- CAR-T cell therapy research 16
- Cutaneous Melanoma Detection and Management 6
-
- Cancer Genomics and Diagnostics 26
- Co-authors
- Richard A. Lempicki (2 shared papers)Da Wei Huang (2 shared papers)Henry Clifford Lane (2 shared papers)Michael Baseler (2 shared papers)Yongjian Guo (2 shared papers)Brad T. Sherman (2 shared papers)Liliana Ossowski (2 shared papers)Robert M. Stephens (1 shared paper)
- Journals
- Blood (9 papers)Nature Communications (6 papers)Cancer Discovery (6 papers)Clinical Cancer Research (5 papers)JCO Precision Oncology (5 papers)
- Partner nations
- United StatesGermanyAustralia
In The Last Decade
David Liu
188 papers receiving 17.8k citations
David Liu's Hit Papers
Peers
Comparison fields: 5 of 182
- Oncology 5.8k
- Cancer Research 3.0k
- Immunology 2.6k
- Molecular Biology 7.1k
- Pulmonary and Respiratory Medicine 2.9k
Countries citing papers authored by David Liu
This map shows the geographic impact of David Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Liu more than expected).
Fields of papers citing papers by David Liu
This network shows the impact of papers produced by David Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Liu. The network helps show where David Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside David Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 196 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists Hit paper breakdown → | 2007 | 1784 |
| 2 | AACR Project GENIE: Powering Precision Medicine through an International Consortium Hit paper breakdown → | 2017 | 1437 |
| 3 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2014 | 1259 |
| 4 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade Hit paper breakdown → | 2018 | 1015 |
| 5 | Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma Hit paper breakdown → | 2019 | 740 |
| 6 | The long tail of oncogenic drivers in prostate cancer Hit paper breakdown → | 2018 | 649 |
| 7 | Engineered pegRNAs improve prime editing efficiency Hit paper breakdown → | 2021 | 541 |
| 8 | A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo Hit paper breakdown → | 2015 | 492 |
| 9 | 2007 | 461 | |
| 10 | Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing Hit paper breakdown → | 2021 | 461 |
| 11 | Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors Hit paper breakdown → | 2018 | 452 |
| 12 | 2001 | 406 | |
| 13 | 2002 | 355 | |
| 14 | 2009 | 332 | |
| 15 | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma Hit paper breakdown → | 2019 | 320 |
| 16 | Adopt a moratorium on heritable genome editing Hit paper breakdown → | 2019 | 309 |
| 17 | 1998 | 303 | |
| 18 | Biologically informed deep neural network for prostate cancer discovery Hit paper breakdown → | 2021 | 297 |
| 19 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma Hit paper breakdown → | 2018 | 288 |
| 20 | 2009 | 246 |
About David Liu
David Liu is a scholar working on Oncology, Cancer Research, Immunology, Molecular Biology and Hematology, having authored 196 papers that have together received 18.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (26 papers), Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (16 papers), Immunotherapy and Immune Responses (12 papers), CRISPR and Genetic Engineering (9 papers), Melanoma and MAPK Pathways (8 papers), Prostate Cancer Treatment and Research (7 papers) and Cutaneous Melanoma Detection and Management (6 papers). The work is most often cited by research in Oncology (5.8k citations), Cancer Research (3.0k citations), Immunology (2.6k citations), Molecular Biology (7.1k citations) and Pulmonary and Respiratory Medicine (2.9k citations). David Liu has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Richard A. Lempicki, Da Wei Huang, Henry Clifford Lane, Michael Baseler, Yongjian Guo, Brad T. Sherman, Liliana Ossowski, Robert M. Stephens, David Bryant and Andrew V. Anzalone. Their work appears in journals such as Blood, Nature Communications, Cancer Discovery, Clinical Cancer Research and JCO Precision Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.